GlassScriptPhysician profile
Mark L Repka
NPI 1235132945
$1,608.84
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $563.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $451.56 | 2019-2020 | |
| Amgen INC. | $249.49 | 2019-2020 | |
| Therapeuticsmd, INC. | $241.91 | 2019-2020 | |
| Renovia INC | $131.69 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $95.82 | 2019-2020 | |
| Allergan, INC. | $95.41 | 2019-2020 | |
| Avion Pharmaceuticals | $57.23 | 2019-2020 | |
| Exeltis, USA INC. | $53.23 | 2019-2020 | |
| Dysis Medical, INC. | $32.87 | 2019 | |
| Lupin INC. | $29.50 | 2019 | |
| Merck Sharp & Dohme LLC | $26.33 | 2019 | |
| Pfizer INC. | $25.60 | 2019-2020 | |
| Millicent US INC | $20.78 | 2019 | |
| Astellas Pharma US INC | $19.37 | 2019 | |
| Coopersurgical, INC. | $19.24 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aesculap, INC. | $15.60 | 2019 | |
| Shire North American Group INC | $15.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.02 | 2019 | |
| Hologic Sales and Service, LLC | $12.73 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Repka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.